Mark Werner, MD
Glaucoma Specialist · Delray Beach, FLNPI 1023033388
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $18,300 of the $23,808 with a category attached, or 76.9%. Bausch & Lomb, A Division Of Bausch Health US, LLC accounts for 88.8% of it on its own, with 24 other manufacturers making up the rest. Reporting peaked in 2019 at $20,724 and has fallen 97.2% since, to $574 in 2025.
Across 122 payments — averaging $195.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb, A Division Of Bausch Health US, LLC$21K
- AbbVie$666
- Alcon$465
- Sumitomo Pharma America, Inc.$219
- Sight Sciences, Inc.$166
- Dompe US, Inc.$154
- plus $992 from 19 others
What the payments were for
- Speaking & faculty fees$18,30077%
- Travel & lodging$2,2599%
- Food & beverage$3,23014%
- Gifts$190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 28 | $21,147 |
| AbbVie(2 entities) | 34 | $666 |
| Alcon | 9 | $465 |
| Sumitomo Pharma America, Inc. | 10 | $219 |
| Sight Sciences, Inc. | 3 | $166 |
| Dompe US, Inc. | 4 | $154 |
| Rxsight Inc | 2 | $125 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $116 |
| Tearlab Corp | 1 | $105 |
| Sun Pharmaceutical Industries Inc. | 3 | $86 |
| Novartis | 4 | $69 |
| Bausch & Lomb Americas Inc. | 4 | $58 |
| Alimera Sciences, Inc. | 2 | $55 |
| Astellas Pharma US Inc | 2 | $54 |
| Ocular Therapeutix, Inc. | 2 | $50 |
| Regeneron Healthcare Solutions, Inc. | 2 | $49 |
| Amgen | 2 | $44 |
| Eyevance Pharmaceuticals LLC | 2 | $35 |
| Glaukos Corporation | 1 | $28 |
| Gilead | 1 | $21 |
| NEW World Medical,inc. | 1 | $20 |
| Omeros Corporation | 1 | $20 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Rayner Intraocular Lenses Limited | 1 | $19 |
| Tarsus Pharmaceuticals, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$23,808 in reported general payments places this provider in the 85th percentile of 31 glaucoma specialist providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 37 | $32,457 |
| LumiganBimatoprost | 59 | $31,537 |
| VyzultaLatanoprostene Bunod | 28 | $22,811 |
| RhopressaNetarsudil Mesylate | 42 | $21,853 |
| XiidraLifitegrast | 20 | $20,482 |
| RocklatanNetarsudil Mesylat/Latanoprost | 47 | $19,964 |
| Alphagan PBrimonidine Tartrate | 39 | $15,174 |
| Prednisolone Acetate | 348 | $11,957 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 38 | $10,923 |
| Methazolamide | 40 | $10,795 |
| Brinzolamide | 56 | $9,896 |
| Latanoprost | 776 | $9,873 |
| Cyclosporine | 18 | $6,414 |
| Travoprost | 31 | $6,346 |
| CombiganBrimonidine Tartrate/Timolol | 14 | $6,240 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Alphagan P, Combigan | $666 | $85,409149 claims |
| Bausch & Lomb Americas Inc.Vyzulta, Xiidra | $58 | $43,29348 claims |
| AlconSimbrinza | $465 | $10,92338 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 31 glaucoma specialist providers in Florida.
Other glaucoma specialist in Delray Beach
- Daniel JewelewiczDelray Beach$9K
- Analisa ArosemenaMiami Beach$438K
- Steven VoldWinter Garden$413K
- Matthew BrinkPalm Beach Gardens$159K
- David GreenfieldMiami$32K
- Dan ArreazaHialeah$9K
- Joah AliancyPort Orange$7K
- Phil AlabataCrestview$7K
- Clinton SheetsHudson$7K
- Norman LevyGainesville$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.